"L'IUCT Oncopole est composé de l'Institut Claudius Regaud, centre de lutte contre le cancer et de plusieurs équipes du CHU de Toulouse. Sur un même site, les deux établissements réunissent l'expertise de 1500 professionnels spécialisés en cancérologie. L'Institut est situé au cœur d'un campus regroupant des acteurs privés et publics investis dans la lutte contre le cancer. Trois missions lui sont confiées : le soin, la recherche et l'enseignement."

During the past decade, Hematologie CHU Purpan conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hematologie CHU Purpan" #1 sponsor was "Lymphoma Study Association" with 5 trials, followed by "Celgene" with 2 trials sponsored, "Intergroupe Francophone du Myelome" with 2 trials sponsored, "Millennium Pharmaceuticals, Inc." with 2 trials sponsored and "University Hospital, Bordeaux" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hematologie CHU Purpan" #1 collaborator was "Amgen" with 4 trials as a collaborator, "HOVON - Dutch Haemato-Oncology Association" with 2 trials as a collaborator, "Australasian Leukaemia and Lymphoma Group" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Hematologie CHU Purpan" are "Multiple Myeloma" (6 trials), "Diffuse Large Cell Lymphoma" (3 trials), "Acute Myeloid Leukemia" (1 trials), "Diffuse Large-Cell Lymphoma" (1 trials) and "Follicular Lymphoma" (1 trials). Many other conditions were trialed in "Hematologie CHU Purpan" in a lesser frequency.

Most popular intervention types in "Hematologie CHU Purpan" are "Drug" (15 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "rituximab" (4 trials), "bortezomib" (2 trials), "cyclophosphamide" (2 trials), "doxorubicin" (2 trials) and "ASCT" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hematologie CHU Purpan" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Hematologie CHU Purpan". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Hematologie CHU Purpan, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hematologie CHU Purpan, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".